PMID- 25241554
OWN - NLM
STAT- MEDLINE
DCOM- 20141104
LR  - 20141120
IS  - 2067-2993 (Print)
IS  - 2067-2993 (Linking)
VI  - 63
IP  - 2
DP  - 2014 Apr-Jun
TI  - [Uptodate in the management and treatment of ANCA-associated vasculitis].
PG  - 78-80, 83-6
AB  - The antineutrophil cytoplasm antibody (ANCA)-associated vasculitis are 
      heterogeneous, multisystem, autoimmune diseases characterized by necrotizing 
      small and medium vessel vasculitis and the association with ANCA. The diagnosis 
      and management of these patients may be challenging due to the variability of 
      clinical features, the possibility of life-threatening events (acute renal 
      failure or pulmonary hemorrhage) and the relative rarity of these syndromes. 
      ANCA-associated vasculitis include granulomatosis with polyangiitis, microscopic 
      polyangiitis and eosinophilic granulomatosis with polyangiitis. The treatment 
      requires significant immunosuppression and there are frequent treatment related 
      side effects. Although the standard protocol with cytotoxic agents and 
      glucocorticoids has dramatically improved patient outcome, its toxic profile 
      remains a major problem. Recent progress in evidence base and consensus in 
      understanding the pathogenic mechanism and the quantification of disease activity 
      further improved patient's life. Special attention was paid in refining 
      immunosuppressive treatment to minimize his toxicity. This review will focus on 
      evidence based treatment of ANCA-associated vasculitis.
FAU - Belaconi, Ionela Nicoleta
AU  - Belaconi IN
FAU - Toma, Claudia Lucia
AU  - Toma CL
FAU - Bogdan, Miron Alexandru
AU  - Bogdan MA
LA  - rum
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Noutati in managementul si tratamentul vasculitelor asociate cu ANCA.
PL  - Romania
TA  - Pneumologia
JT  - Pneumologia (Bucharest, Romania)
JID - 100941067
RN  - 0 (Glucocorticoids)
RN  - 0 (Immunosuppressive Agents)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
MH  - Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/diagnosis/*drug 
      therapy
MH  - Cyclophosphamide/*therapeutic use
MH  - Diagnosis, Differential
MH  - Drug Therapy, Combination
MH  - Evidence-Based Medicine
MH  - Glucocorticoids/*therapeutic use
MH  - Granulomatosis with Polyangiitis/drug therapy
MH  - Humans
MH  - Immunosuppressive Agents/*therapeutic use
MH  - Methotrexate/*therapeutic use
MH  - Prognosis
MH  - Randomized Controlled Trials as Topic
MH  - Remission Induction
MH  - Severity of Illness Index
MH  - Treatment Outcome
EDAT- 2014/09/23 06:00
MHDA- 2014/11/05 06:00
CRDT- 2014/09/23 06:00
PHST- 2014/09/23 06:00 [entrez]
PHST- 2014/09/23 06:00 [pubmed]
PHST- 2014/11/05 06:00 [medline]
PST - ppublish
SO  - Pneumologia. 2014 Apr-Jun;63(2):78-80, 83-6.